Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06370754
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-17
First Post:
2024-04-15
Brief Title:
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Phase IbII Platform Trial of Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FD-IMPACT
Brief Summary:
This is a Phase IbII platform clinical study to evaluate the initial efficacy and safety of different novel immunotherapies in patients with advanced pancreatic cancer
Detailed Description:
The cohort ABC included patients with unresectable locally advanced or metastatic pancreatic cancer who had previously failed at least first line gemcitabine-based system therapyThe cohort DEF included patients with previously untreated systemic pancreatic cancer with unresectable locally advanced or metastatic pancreatic cancerThis study plans to first explore ABC cohort and then start the DEF cohort after determining the safety
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None